GAINESVILLE, Fla., Oct. 31, 2014 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced it has successfully filed its second U.S. Provisional Patent Application. The Company's Chief Operating Officer, Gene Elliott, is leading the Company's facility validation initiatives using a GAMP® 5 compliance approach.
Chris Broderick, Chief Executive Officer, states, "This additional patent filing has improved our position in regards to protecting our early-stage technology, and we are excited at the upfront implementation of such technical quality management systems at our facility to support our anticipated growth and evolving industry regulations."
The Company's Chief Technology Officer, Dr. Sean O'Connell, is leading the Company through developing a biological profile of its early-stage technologies, ProLifxTM and AmnioCelTM, both minimally manipulated amniotic collagen matrix products.
About AmnioLife
AmnioLife is a human cells, tissues, and cellular and tissue-based products developer focused on placental-derived technologies, and is building a quality system around GTP and GMP at its manufacturing and research facility located in Gainesville, FL. The Company aims to develop a strong intellectual property position, global sales channel partners, and has a seasoned management and advisory team. For more information, visit our website at http://www.amniolife.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws that are forward-looking, and based on the current expectations and beliefs of AmnioLife's management team. The forward-looking statements contained in this press release are subject to a number of factors and uncertainties that could cause actual results to differ materially. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and marketplace requirements; delays or obstacles in launching and/or successfully completing some of the clinical study initiatives; products may not be approved by regulatory agencies or regulations may change affecting desired results; inability to retain or attract key employees whose knowledge is essential to the development of required technologies and products; unforeseen scientific difficulties may develop with our process; our patent(s) may not be sufficient; inability to timely develop and introduce new technologies; inability to obtain additional funding; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of AmnioLife to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, AmnioLife disclaims any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.